A Phase 2 Study Of Dabrafenib (NSC# 763760) With Trametinib (NSC# 763093) After Local Irradiation In Actively-Diagnosed BRAF V600-Mutant High-Grade Glioma (HGG) Read more
A Phase 2 Study Of Veliparib (ABT-888) And Local Irradiation, Followed By Maintenance Veliparib And Temozolomide, In Patients With Actively Diagnosed High-Grade Glioma (HGG) Without H3 K27M Or BRAFV600 Mutations Read more
A Phase 3 Randomized Non-Inferiority Study Of Carboplatin And Vincristine Versus Selumetinib (NSC# 748727) In Actively Diagnosed Or Previously Untreated Low-Grade Glioma (LGG) Not Associated With BRAFV600E Mutations Or Systemic Neurofibromatosis Type 1 (NF1) Read more
A Phase 2, Open-Label Study Of Encorafenib + Binimetinib In Patients With BRAFV600E-Mutant Non-Small Cell Lung Cancer Read more
A Phase 1/2 Feasibility, Safety, And Activity Study Of PSCA-Specific Chimeric Antigen Receptor Engineered T Cells (BPX-601) In Subjects With Previously Treated Advanced Solid Tumors Read more
A Phase 1/2, Open-Label, Multicenter, Non-Randomized, Safety And Activity Study Of Her-Targeted Dual Switch Car-T Cells (Bpx-603) In Subjects With Previously Treated Advanced Her2-Positive Solid Tumors Read more
Phase 1/2a First-In-Human Study Of BMS-986207 Monoclonal Antibody Alone And In Combination With Nivolumab In Advanced Solid Tumors Read more
Phase 1/2a First-In-Human Study Of BMS-986218 Monoclonal Antibody Alone And In Combination With Nivolumab In Advanced Solid Tumors Read more
